Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ATRA Atara Biotherapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ATRA
Price (delayed)
$6.84
Market cap
$40.78M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.57
Enterprise value
$92.88M
Atara Biotherapeutics, Inc.(@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers
Highlights
The EPS has soared by 95% YoY and by 77% from the previous quarter
The net income has soared by 93% YoY and by 82% from the previous quarter
Atara Biotherapeutics's gross margin has increased by 16% YoY but it has decreased by 4.2% QoQ
Key stats
What are the main financial stats of ATRA
Market
Valuations
Earnings
Shares outstanding
5.96M
Market cap
$40.78M
Enterprise value
$92.88M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.37
EV/EBIT
N/A
EV/EBITDA
12.59
EV/Sales
0.47
Revenue
$199.73M
Gross profit
$160.27M
Operating income
-$13.39M
Net income
-$15.64M
EBIT
-$11.2M
EBITDA
$7.38M
Free cash flow
-$67.36M
Per share
Balance sheet
Liquidity
EPS
-$2.57
EPS diluted
-$2.6
Free cash flow per share
-$6.26
Book value per share
-$9.4
Revenue per share
$18.56
TBVPS
$5.76
Total assets
$62.04M
Total liabilities
$117.11M
Debt
$66.09M
Equity
-$55.07M
Working capital
-$20.71M
Debt to equity
-1.2
Current ratio
0.57
Quick ratio
0.48
Net debt/EBITDA
7.06
Margins
Efficiency
Dividend
EBITDA margin
3.7%
Gross margin
80.2%
Net margin
-7.8%
Operating margin
-6.7%
Return on assets
-14.5%
Return on equity
N/A
Return on invested capital
-40.8%
Return on capital employed
-79.2%
Return on sales
-5.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATRA stock price
How has the Atara Biotherapeutics stock price performed over time
Intraday
-10.12%
1 week
-5.91%
1 month
17.12%
1 year
-54.67%
YTD
-48.61%
QTD
15.15%
Financial performance
How have Atara Biotherapeutics's revenue and profit performed over time
Revenue
$199.73M
Gross profit
$160.27M
Operating income
-$13.39M
Net income
-$15.64M
Gross margin
80.2%
Net margin
-7.8%
The net margin has soared by 99% YoY and by 88% from the previous quarter
ATRA's operating margin has surged by 99% year-on-year and by 90% since the previous quarter
The operating income has soared by 94% YoY and by 84% from the previous quarter
The net income has soared by 93% YoY and by 82% from the previous quarter
Price vs fundamentals
How does ATRA's price correlate with its fundamentals
Growth
What is Atara Biotherapeutics's growth rate over time
Valuation
What is Atara Biotherapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.37
EV/EBIT
N/A
EV/EBITDA
12.59
EV/Sales
0.47
The EPS has soared by 95% YoY and by 77% from the previous quarter
The equity has grown by 44% year-on-year and by 43% since the previous quarter
ATRA's P/S is 99% below its 5-year quarterly average of 53.1 and 38% below its last 4 quarters average of 0.6
Atara Biotherapeutics's revenue has surged by 55% QoQ
Efficiency
How efficient is Atara Biotherapeutics business performance
The ROS has soared by 99% YoY and by 91% from the previous quarter
Atara Biotherapeutics's return on invested capital has surged by 91% QoQ and by 80% YoY
The company's return on assets has surged by 88% YoY and by 77% QoQ
Dividends
What is ATRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATRA.
Financial health
How did Atara Biotherapeutics financials performed over time
The total assets is 47% less than the total liabilities
The total assets has plunged by 62% YoY and by 43% from the previous quarter
ATRA's total liabilities has dropped by 56% year-on-year and by 43% since the previous quarter
ATRA's debt to equity has dropped by 71% since the previous quarter and by 52% year-on-year
The equity has grown by 44% year-on-year and by 43% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.